<DOC>
	<DOCNO>NCT02772198</DOCNO>
	<brief_summary>This phase 1 / 2 study evaluate response B-cell malignancy express CD19 autologous T cell transduce second generation anti-CD19 chimeric antigen receptor child young adult .</brief_summary>
	<brief_title>T-cells Expressing Anti-CD19 CAR Pediatric Young Adults With B-cell Malignancies</brief_title>
	<detailed_description>Autologous T cell transduce chimeric antigen receptor ( CAR ) recognize CD19 antigen ( CD19-CAR T cell ) use multiple clinical trial several institution worldwide . We establish in-house manufacturing process CD19-CAR T cell CD28 ( cluster differentiation 28 ) costimulatory domain . Primary Objectives : 1 . To study safety administration CAR T cell Sheba Medical Center 2 . To determine feasibility efficacy administer anti-CD19-CAR T cell child young adult B cell malignancy . Secondary Objectives 1 . To study vivo vitro behavior CAR T cell patient , include persistence , expansion , cytotoxic potential exhaustion . 2 . To study cytokine milieu CAR treat patient . Eligibility Patients 1-39 year age , CD19-expressing B-cell malignancy recur , respond , one standard chemotherapy-containing regimen . Design Peripheral blood mononuclear cell ( PBMCs ) obtain leukapheresis . Anti-CD19 CAR T cell manufacture fresh autologous PBMCs . PBMC culture presence anti-CD3 ( cluster differentiation 3 ) antibody interleukin-2 follow retroviral vector supernatant contain anti-CD19 CAR . Total culture time 7-10 day . Patients receive lymphodepleting chemotherapy compose cyclophosphamide fludarabine prior cell infusion , day 0 receive one million CAR T cell per kilogram . Patients monitor toxicity include cytokine release syndrome , hematologic toxicity B-cell aplasia ; response underlying malignancy ; CAR-T cell persistence blood , marrow cerebral spinal fluid ( CSF ) .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Patient relapse refractory Bcell malignancy Age 139 year CD19 expression show flow cytometry immunohistochemistry least 70 % leukemic blast / lymphoma cell Adequate CD3 count ( 250 CD3+ cell per microliter blood ) Clinical performance status : Patients &gt; 10 year age : Karnofsky ≥ 50 % ; Patients ≤ 10 year age : Lansky scale ≥ 50 % . Exception neurologic symptom ( e.g . paralysis ) explain malignancy . Females childbearing potential must negative pregnancy test Cardiac function : Left ventricular ejection fraction &gt; 45 % shorten fraction &gt; 28 % For patient follow allogeneic bone marrow transplantation least 100 day post BMT sign symptom active graftversushost disease . Key Hyperleukocytosis ( WBC &gt; 50,000 ) rapidly progressive disease Pregnant breastfeeding female Hepatic dysfunction , define bilirubin &gt; x2 upper normal limit ( except explain hemolysis Gilbert ) serum glutamate oxaloacetate transaminase &gt; x25 upper normal limit . Hepatitis B , Hepatitis C HIV infection . Antineoplastic treatment give 2 week prior apheresis , exception intrathecal chemotherapy . Active immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>